Articles related to PROSTATE CANCER

An inhibitor of poly(ADP-ribose) polymerase (PARP), rucaparib, demonstrated high levels of efficacy in patients with metastatic, castration-resistant prostate cancer coupled with a harmful BRCA change in a phase 2 research. To support and add to the findings of the phase 2 trial, data are required.

The purpose of this study was to assess the relationship between the RTOG clinical target volumes (CTVs) and PSMA PET-defined recurrence topography, as well as to analyze the patterns of prostate bed (PB) recurrence in prostate cancer patients who had PSA persistence (BCP) or biochemical recurrence (BCR) following radical prostatectomy.

A group of UK researchers has created a novel prostate cancer (PaC) screening test (EpiSwitch) that, when combined with the prostate specific antigen (PSA) test, has a high degree of accuracy for detecting the cancer. The test is based on measurement of five chromosome conformations that were first discovered in association with advanced PaC. The EpiSwitch test has a high positive predictive value for the diagnosis of PaC (92%) and a high negative predictive value (94%) when used in conjunction with the PSA level as a continuous variable, according to the researchers. The study’s authors advocated for additional research to investigate the test’s efficacy in larger patient samples, even though it was based on a scant number of patient samples.

The first standalone AI-based cancer diagnostics product of its kind to receive Vitro Diagnostic Medical Devices Regulation (IVDR) certification is Galen Prostate. Ibex intends to transition more goods, such as its Galen Breast and Galen Gastric solutions, under the IVDR accreditation during 2023.

The development of new androgen receptor pathway inhibitors (ARPis) has resulted in a dramatic therapeutic paradigm change for the older adult illness of prostate cancer. Enzalutamide is one of the ARPis that is used more frequently. Darolutamide, apalutamide, and this medication were all first approved for the treatment of metastatic castrate-resistant prostate cancer, but they are now routinely used in the treatment of metastatic castrate-sensitive and non-metastatic castration-resistant prostate cancer. Only older persons with outstanding performance status are included in landmark phase III data demonstrating the effectiveness of ARPi in these patients. However, in the context of a narrative review, its function in older prostate cancer patients who are ineligible has to be investigated.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.